{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T08:33:14Z","timestamp":1790757194954,"version":"4.1.0"},"reference-count":23,"publisher":"SAGE Publications","issue":"6","license":[{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Int Med Res"],"published-print":{"date-parts":[[2021,6]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To describe the characteristics, management and outcomes of hospitalised patients with Clostridioides difficile infection (CDI) treated with and without fidaxomicin.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This prospective, multicentre, observational study (DAFNE) enrolled hospitalised patients with CDI, including 294 patients treated with fidaxomicin (outcomes recorded over a 3-month period) and 150 patients treated with other CDI therapies during three 1-month periods. The primary endpoint was baseline and CDI characteristics of fidaxomicin-treated patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>At baseline, the fidaxomicin-treated population included immunocompromised patients (39.1%) and patients with severe (59.2%) and recurrent (36.4%) CDI. Fidaxomicin was associated with a high rate of clinical cure (92.2%) and low CDI recurrence (16.3% within 3 months). Clinical cure rates were \u226590% in patients aged \u226565 years, those receiving concomitant antibiotics and those with prior or severe CDI. There were 121\/296 (40.9%) patients with adverse events (AEs), 5.4% with fidaxomicin-related AEs and 1.0% with serious fidaxomicin-related AEs. No fidaxomicin-related deaths were reported.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Fidaxomicin is an effective and well-tolerated CDI treatment in a real-world setting in France, which included patients at high risk of adverse outcomes. Trial registration: Description of the use of fidaxomicin in hospitalised patients with documented Clostridium difficile infection and the management of these patients (DAFNE), NCT02214771, www.ClinicalTrials.gov.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/03000605211021278","type":"journal-article","created":{"date-parts":[[2021,6,24]],"date-time":"2021-06-24T02:22:07Z","timestamp":1624501327000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":9,"title":["A prospective, observational study of fidaxomicin use for\n                    <i>Clostridioides difficile<\/i>\n                    infection in France"],"prefix":"10.1177","volume":"49","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6526-0714","authenticated-orcid":false,"given":"Benoit","family":"Guery","sequence":"first","affiliation":[{"name":"University Hospital and University of Lausanne, Lausanne, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Berger","sequence":"additional","affiliation":[{"name":"Paoli-Calmettes Institute, Marseille, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Remy","family":"Gauzit","sequence":"additional","affiliation":[{"name":"Cochin University Hospital, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magali","family":"Gourdon","sequence":"additional","affiliation":[{"name":"Astellas Pharma S.A.S., Levallois-Perret, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fr\u00e9d\u00e9ric","family":"Barbut","sequence":"additional","affiliation":[{"name":"National Reference Laboratory for C. difficile, Saint-Antoine Hospital, Paris, France"},{"name":"INSERM S-1139, Faculty of Pharmacy, University of Paris, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"for the DAFNE study group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"DAFNE study group:","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pascale","family":"B\u00e9mer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilie","family":"Bess\u00e8de","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabrice","family":"Camou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Cattoir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carine","family":"Couzigou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominique","family":"Descamps","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aur\u00e9lien","family":"Dinh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Laurans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Philippe","family":"Lavigne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Lechiche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V\u00e9ronique","family":"Leflon-Guibout","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alban","family":"Le Monnier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marion","family":"Levast","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joy Yoganaden","family":"Mootien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yohan","family":"N\u2019Guyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lionel","family":"Piroth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thierry","family":"Prazuck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Rogeaux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Laure","family":"Roux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Vach\u00e9e","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V\u00e9ronique","family":"Vernet Garnier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fr\u00e9d\u00e9ric","family":"Wallet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2021,6,23]]},"reference":[{"key":"bibr1-03000605211021278","doi-asserted-by":"publisher","DOI":"10.1038\/nature13828"},{"key":"bibr2-03000605211021278","doi-asserted-by":"publisher","DOI":"10.1038\/nrdp.2016.20"},{"key":"bibr3-03000605211021278","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(14)70991-0"},{"key":"bibr4-03000605211021278","doi-asserted-by":"publisher","DOI":"10.1111\/1469-0691.12064"},{"key":"bibr5-03000605211021278","doi-asserted-by":"publisher","DOI":"10.1111\/1469-0691.12418"},{"key":"bibr6-03000605211021278","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cix1085"},{"key":"bibr7-03000605211021278","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(18)30285-8"},{"key":"bibr8-03000605211021278","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhin.2015.03.001"},{"key":"bibr9-03000605211021278","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cis338"},{"key":"bibr10-03000605211021278","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2017.12.022"},{"key":"bibr11-03000605211021278","doi-asserted-by":"publisher","DOI":"10.1038\/ctg.2013.13"},{"key":"bibr12-03000605211021278","doi-asserted-by":"publisher","DOI":"10.1007\/s15010-017-0981-8"},{"key":"bibr13-03000605211021278","doi-asserted-by":"publisher","DOI":"10.1007\/s10096-016-2802-x"},{"key":"bibr14-03000605211021278","doi-asserted-by":"publisher","DOI":"10.1097\/MCG.0000000000000769"},{"key":"bibr15-03000605211021278","doi-asserted-by":"publisher","DOI":"10.1007\/s11136-011-9903-x"},{"key":"bibr16-03000605211021278","doi-asserted-by":"publisher","DOI":"10.1111\/j.1469-0691.2006.01580.x"},{"key":"bibr17-03000605211021278","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(11)70374-7"},{"key":"bibr18-03000605211021278","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0910812"},{"key":"bibr19-03000605211021278","unstructured":"Astellas Pharma Europe B.V. Summary of Product Characteristics: DIFICLIR 200 mg film-coated tablets, https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/dificlir-epar-product-information_en.pdf (2016)."},{"key":"bibr20-03000605211021278","doi-asserted-by":"publisher","DOI":"10.1086\/651706"},{"key":"bibr21-03000605211021278","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciu313"},{"key":"bibr22-03000605211021278","doi-asserted-by":"publisher","DOI":"10.1186\/s12955-019-1081-5"},{"key":"bibr23-03000605211021278","doi-asserted-by":"publisher","DOI":"10.1007\/s10620-018-5222-1"}],"container-title":["Journal of International Medical Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/03000605211021278","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/03000605211021278","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/03000605211021278","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T10:47:51Z","timestamp":1777459671000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/03000605211021278"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6]]},"references-count":23,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,6]]}},"alternative-id":["10.1177\/03000605211021278"],"URL":"https:\/\/doi.org\/10.1177\/03000605211021278","relation":{},"ISSN":["0300-0605","1473-2300"],"issn-type":[{"value":"0300-0605","type":"print"},{"value":"1473-2300","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6]]},"article-number":"03000605211021278"}}